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Abstract Growth hormone (GH) is
fundamental for the maintenance
of bone mass and metabolism both
during childhood and in adulthood.
This effect is due to a complex
interaction between circulating GH
and IGF-I produced peripherally.
In vitro data and experimental ani-
mal models have clarified many of
the regulatory mechanisms under-
lying the characteristic skeletal
changes occurring in acromegaly.
This review focuses on
the effects of GH excess on bone
metabolism and mass in acrome-
galic patients and, in particular, on
the influence of factors such as
hypogonadism, gender, age and
therapy on bone metabolism and
arthropathy.
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also synthesized [3]. GH also stimulates production of
IGFBP3 and ALS, other components of the high molecu-
lar weight IGF ternary complex, in the liver [3].
Some IGFBPs, in particular types 3 and 5, not only
inhibit IGF action by competing with the membrane
receptor but also may potentiate IGF action, probably
because they bind to the cell membrane or to the extracel-
lular matrix and protect IGF from being degraded by pro-
teases [4]. IGFBP proteases are produced ubiquitously
and can act in an autocrine or paracrine way on the IGF
system [5].
Lastly, IGF activity (particularly IGF-II) also depends
on binding to vitronectin in the extracellular matrix,
which potentiates IGF action [6], and to the integrin
receptor which influences intracellular signalling of the
type 1 receptor [7, 8].
Regarding bone, a direct effect of GH and IGF-I on
osteoblasts was demonstrated by the finding of functional
GH and IGF-I receptors in human and rat osteoblast cul-
Introduction
Longitudinal bone growth during childhood is due to
growth hormone (GH)-dependent stimulation of precursor
cells in epiphyseal cartilage, while maintenance of adult
bone mass results from GH-driven bone modelling
processes [1, 2]. These effects are the consequence of
complex interactions between systemic GH, insulin-like
growth factor (IGF) I and II, IGF binding proteins (BPs)
and locally produced IGF-I and IGFBPs (Figs. 1, 2).
IGF-I and IGF-II interact with two specific receptors:
the type 1 receptor, through which mitogenic and func-
tional effects are activated; and the type 2 receptor, which
probably inhibits IGF activity by competing with type 1
receptor binding. IGF-I and IGF-II also cross-react with
the insulin receptor. IGF-I production is mainly stimulat-
ed by the action of GH in liver, although it takes place in
all peripheral tissues, where IGF-II and the IGFBPs are
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tures [9, 10]. GH and IGF-I regulate osteoblast prolifera-
tion, with GH exerting a prominent IGF-I-independent
effect on differentiation, and IGF-I acting mainly on differ-
entiated osteoblasts. Canalis et al. [11] first reported that
osteoblasts produce IGF-I and that IGF-I has a mitogenic
action on bone cells. Osteoblasts also synthesize IGF-II,
and the balance between IGF-I and IGF-II production
depends on the different bone districts. Further insight into
the role of systemic IGF-I in the development and mainte-
nance of adult bone mass has recently been acquired by the
use of global and liver IGF-I knockout mice: in the former
a reduction in bone size and an increase in trabecular bone
volume was observed [12], due to increased connective tis-
sue; the latter knockout mice have reduced cortical bone
mineral density with no changes in trabecular bone.
Moreover, IGF-I overexpression increases bone mineral
density and trabecular bone volume [13], while GH overex-
pression initially leads to increased bone formation and
subsequently to increased bone resorption [14].
Local inhibitors of IGF synthesis are transforming
growth factor β (TGF-β) and cortisol [15, 16], while
parathyroid hormone (PTH) exerts a stimulatory effect [17,
18]. IGFs also regulate production of collagen and matrix
apposition [19]. In addition, GH, IGF-I and IGFBPs may
all modulate osteoclast function and thus bone resorption
[20]. Lastly, IGFBP-2 to -5 have also been demonstrated to
be present in bone. In particular, IGFBP-4 has an inhibit-
ing effect on IGF action, while IGFBP-5 has a potentiating
effect, both in vitro and in vivo, probably by binding to
sites independent of the type 1 IGF receptor [21].
Bone metabolism and density in acromegaly
In acromegaly (Fig. 3), changes in skeletal structure and
metabolism are due to the chronic GH and IGF-I overpro-
duction. Biochemical markers of bone remodelling are
Fig. 2 Effects of GH and IGF-I on bone cells. GH acts both osteo-
blasts, stimulating differentiation and proliferation, and on osteo-
clasts, enhancing their recruitment and activity. IGF-I exerts an
anabolic effect through stimulation of collagen synyhesis and
osteoblast proliferation, while its action on osteoclasts results in
increased bone resorption (GH growth hormone; IGF-I insulin-
linke growth factor)
Fig. 3a, b Acromegaly. a Typical acromegalic face. b MR image of
pituitary shows macroadenoma in an acromegalic patient
a
b
Fig. 1 The GH/IGF-I system and bone interactions. Pituitary GH
acts on skeletal tissue both directly, stimulating osteblast prolifera-
tion, and indirectly, via liver IGF-I production. IGF-I mainly acts on
osteoblast proliferation, and, together with GH and IGF-BPs, mod-
ulates osteoclast function (GH growth hormone; IGF-I insulin-like
growth factor; IGF-BPs insulin-like growth factor binding proteins)
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increased, and correlate well with circulating GH and
IGF-I levels [9, 10]. In particular, urinary excretion of
hydroxyproline and creatinine is increased in the vast
majority of acromegalic patients and correlates with plas-
ma IGF-I levels; however, a more specific indicator of
bone collagen turnover, urinary type I collagen cross-
linked N-telopeptide, correlates with serum GH [22].
Moreover, most markers rapidly decrease during effective
treatment [23–26]. It is of particular interest to note that
the controlled selective blockade of the GH receptor by
the antagonist pegvisomant in acromegaly resulted in
decreased measures of both bone formation and resorp-
tion. In fact, in a 12-week placebo-controlled trial, admin-
istration of pegvisomant was associated with a significant
reduction in bone turnover markers osteocalcin, serum
procollagen I carboxy-terminal propeptide and N-telopep-
tide [24]. The use of this experimental model is of partic-
ular interest because it rules out possible interfering
actions on bone of other drugs used in the treatment of
acromegaly, such as somatostatin analogs.
The increase in bone mass typically involves cortical
bone, while for trabecular bone data are not unequivocal.
Earlier studies reported a high prevalence of osteoporosis
in acromegalic patients, despite low fracture rates. In fact,
vertebral bone density is normal or slightly reduced in
these patients, while limbs generally have increased den-
sity [22, 27–30]. Vestergaard and Mosekilde [31] observed
that, in a large cohort of newly diagnosed acromegalic
patients who underwent surgery, the fracture rate was sig-
nificantly lower before surgery as compared with controls,
as a consequence of the anabolic effects of GH on bone
[31]. Normal or increased bone mineral density (BMD) at
the femoral neck and lumbar spine was recently observed
[32] in patients in remission after treatment for
acromegaly. Similar results were obtained in patients in
remission for 5 years or longer. No relationship between
BMD and disease severity or duration was found before
treatment. Thus, the anabolic effect of GH on trabecular
and cortical bone appears to persist after remission of
acromegaly. On the other hand, other studies failed to
observe significant differences in BMD between acrome-
galic patients and controls [27, 33]. This discrepancy
could be due to differences in skeletal sites examined,
diagnostic equipment used, and grouping of patients
regardless of gender and gonadal status.
Gonadal status may influence the effects of GH and
IGF-I excess on bone [34]. Femoral BMD is increased
only in acromegalic patients with active disease, regardless
of gonadal status, and vertebral BMD only in eugonadal
patients, regardless of disease activity. Furthermore, these
effects are gender-independent. The same authors [35]
reported that bone density forearm is normal, while bone
density in the femur increases independently of the
gonadal status; moreover an increased bone mass can be
documented in the spine, but not in the femur or in the
forearm in eugonadal patients, while hypogonadal patients
have values of trabecular bone mass at both sites similar to
those in the matched controls. Other authors reported
increased BMD in eugonadal acromegalic patients, at both
femoral and lumbar spine levels [36]. Overall, GH and
IGF-I excesses increase the cortical bone density, regard-
less of age and gonadal function, while hypogonadism
seems to counteract the anabolic effect of GH on the tra-
becular bone of young and middle-aged patients [37]. The
implications of these finding are that eugonadal acrome-
galic patients are not at risk of decreased lumbar spine and
femoral neck BMD. However, if these patients develop
hypogonadism, they may be at risk of reduced lumbar
spine BMD and osteoporosis [36]. Thus, it may be advis-
able to screen for hypogonadism and to start hormone
replacement therapy as soon as it is diagnosed.
Acromegalic arthropathy
Acromegalic patients often complain of symptoms due to
acromegalic arthropathy, a condition characterized by
osteophytosis, reduced articular space and calcification of
ligamentous insertions and joint capsules (Fig. 4) [1, 38,
39]. GH and IGF-I excesses are responsible for replication
of articular chondrocytes and increased matrix synthesis
[1]. As a result, there is thickening of the cartilage, widen-
ing of the joint space, alteration of normal joint geometry
and hypermobillity. Moreover, GH and IGF-I stimulate
Fig. 4a-d Articular modifications in acromegaly. a, b Hands.
c, d Feet
a
c
b
d
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growth of periarticular structures and cause sinovial
hypertrophy, which in turn exacerbates the abnormal
mechanical loading of the joint. Effective treatment of
acromegalic disease at this stage can stop arthropathy pro-
gression and even reverse manifestations, but when degen-
erative changes have progressed and fissures of the carti-
lage surface have appeared, alterations may become per-
manent [38, 40].
Therefore, joint thickness may also be increased in
patients cured by surgery compared to controls [38]. At
this stage there are in fact calcifications and osteophyte
formation, cartilagineous fissures extend to the subchon-
dral bone, articular cartilage becomes ulcerated while
bones show accelerated turnover, eburnation and subchon-
dral cyst formation [1]. Eventually, thinning of the articu-
lar cartilage and narrowing of the joint space become pre-
dominant features of arthropathy, resembling those of
osteoarthritis. Radiological signs can be detected early in
the course of the disease and usually precede other clinical
manifestations. Ultrasonography is a valuable tool in the
evaluation of periarticular soft tissue structures such as
joint capsules and tendons. By this technique, increased
thickness of both weight-bearing (knees) and non-weight-
bearing (shoulder and wrist) joints can be shown in
patients with active acromegaly compared to controls [41].
The most frequently affected joints are hands, knees
and hips, as well as cervical and lumbosacral spine,
although any joint can be involved. When disease duration
is long, severe degenerative changes may occur at several
levels. Severe arthropathy may be present in up to 40% of
patients, while most patients (75%) present with mild
manifestations (Table 1).
Typical features of acromegaly are prognathism and
widening of the interdental spaces. These changes lead to
dental malocclusion and temporomandibular joint syn-
drome in about one-third of cases. Recently, a rat model of
acromegaly (acrogiantism) was developed to investigate
the time course of mandibular enlargement by continuous
subcutaneous human recombinant IGF-I infusion [42]:
after discontinuation of IGF-I administration, the
mandibula did not continue to grow but did not return to
control size either, at variance with the maxilla and femur.
These data suggest that mandibular occlusal treatment
should be taken into consideration in acromegalic patients
only after serum IGF-I levels have normalized and bone
growth has ceased.
Neurological complications associated with bone alter-
ations
Typical feature of acromegaly is also symptomatic carpal
tunnel syndrome, which affects 20%–60% of patients [1,
43]. Prevalence may be even higher if subclinical conditions
detected by nerve conduction studies are considered [44].
Hand MRI may reveal increased nerve size and signal inten-
sity in patients with symptoms of neuropathy compared with
asymptomatic ones [45]. The major pathogenetic factor for
median neuropathy in acromegaly seems to be increased
edema of the median nerve, but an increase in connective tis-
sue, demyelination of Schwann cells, an increase in extra-
cellular fluid of the carpal bones and bony or synovial over-
growth of carpal bones can be involved as well [37]. It is
interesting to note that while presence and severity of carpal
tunnel syndrome do not seem to correlate with GH and IGF-
I levels, nor with duration of disease, nerve swelling
decreases after successful treatment of acromegalic disease,
suggesting that control of hormone levels is essential for
regression of nerve abnormalities [43, 44].
Respiratory complications
Respiratory disorders of acromegaly are frequent and
complex in their origin and development. Certainly, struc-
tural changes in the upper and lower airways induced by
the hypertrophic action of GH, a decrease in pulmonary
elasticity with a concominant increase in lung volume due
Table 1 Prevalence of arthropathy in acromegaly
Reference Year Mild arthropathy Severe arthropathy
Detenbeck et al. [50] 1973 62% 16%
Bluestone et al. [51] 1971 62% 38%
Dons et al. [52] 1988 76% ND
Podgorsky et al. [53] 1988 74% (peripheral) 28%a
45% (vertebral)
Barkan [39] 1997 ND 30%
ND, not determined; a 22% in men, 35% in women
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to alveoli overgrowth, and hyperstimulation of the respi-
ratory center mediated by the somatostatinergic tone and
triggered by an altered sensitivity threshold to carbon
dioxide are the major factors involved in the pathogenesis
of sleep apnea, the prominent type of breathing disorder
of acromegaly [1]. However, anatomical changes affecting
craniofacial bones and soft tissues, respiratory muscles
and cartilage, lung volume, rib cage geometry and activi-
ty of the respiratory muscles are also involved. 
Acromegalic patients develop a barrel chest due to ky-
phosis caused by changes in vertebral bodies and by elonga-
tion and diversion of the ribs. In particular vertebral bodies
increase in size due to periosteal bony apposition, while the
intervertebral discs become thicker in the cervical and lum-
bar spine, and thinner in the thoracic region [46, 47]. The
epiphyses of the costochondral junctions fail to close and
may cause prominence of the costochondral junction [48].
These anatomical changes impair chest mechanics and mar-
kedly alter the inspiratory muscle activation. Furthermore,
acromegaly is associated with muscle weakness and wasting
due to alterations of type I and type II muscle fibers, small
cell infiltration, thickening of the capillary basement mem-
brane and segmental fiber degeneration, all which may con-
tribute to the impairment of physiological breathing [49].
Conclusions
In conclusion, effects of GH on linear bone growth, bone
metabolism and bone mass are relevant. In vitro, GH stim-
ulates proliferation, differentiation and extracellular
matrix production in osteoblast-like cell lines, as well as
recruitment and bone resorption activity in osteoclast-like
cells. Acromegaly results in increased bone turnover and
appendicular cortical bone mass, while vertebral bone
mass is largely unaffected. However, evaluation of the
effects of GH is frequently obscured by concomitant
hypogonadism. Arthropathy affects most acromegalic
patients and is a leading cause of morbidity and function-
al disability. Only the early stages are seemingly
reversible by effective treatment of the acromegalic dis-
ease, while nothing can be done to stop the vicious cycle
of articular changes in long-term disease.
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